Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus: Network Leadership Center (UM2)

 

The purpose of this FOA is to solicit applications for the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis (RA) and Lupus Network Leadership Center. The AMP RA and Lupus Network is designed to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases. This program will involve an enhanced systems-level understanding of gene expression and signaling in target tissues from affected end organs and peripheral blood cells.

Deleted 06/21/2014 (Archived.) RFA-AR-14-015 Agency: Department of Health and Human Services
Office: National Institutes of Health Cooperative Agreement 1 Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 05/21/2014 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-14-015.html FBOWebmaster@OD.NIH.GOV $1,400,000.00 Awards up to $2,000,000.00